Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)

Trial Profile

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Early breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium
    • 01 Oct 2019 Trial design were presented at the 44th European Society for Medical Oncology Congress
    • 11 Feb 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top